| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NRP1 |
| Uniprot No | O14786 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-644aa |
| 氨基酸序列 | FRNDKCGDTIKIESPGYLTSPGYPHSYHPSEKCEWLIQAPDPYQRIMINFNPHFDLEDRDCKYDYVEVFDGENENGHFRGKFCGKIAPPPVVSSGPFLFIKFVSDYETHGAGFSIRYEIFKRGPECSQNYTTPSGVIKSPGFPEKYPNSLECTYIVFVPKMSEIILEFESFDLEPDSNPPGGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRIRSSSGILSMVFYTDSAIAKEGFSANYSVLQSSVSEDFKCMEALGMESGEIHSDQITASSQYSTNWSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFEVYGCKITDYPCSGMLGMVSGLISDSQITSSNQGDRNWMPENIRLVTSRSGWALPPAPHSYINEWLQIDLGEEKIVRGIIIQGGKHRENKVFMRKFKIGYSNNGSDWKMIMDDSKRKAKSFEGNNNYDTPELRTFPALSTRFIRIYPERATHGGLGLRMELLGCEVEAPTAGPTTPNGNLVDECDDDQANCHSGTGDDFQLTGGTTVLATEKPTVIDSTIQSGIK |
| 预测分子量 | 98.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NRP1(Neuropilin-1)重组蛋白的文献示例(注：以下内容基于公开研究整合，可能需通过学术数据库核实准确性)：
1. **"Structural basis for semaphorin signalling through Neuropilin-1"**
- **作者**: Appleton BA, et al.
- **摘要**: 该研究解析了NRP1重组蛋白与Semaphorin配体结合的晶体结构，揭示了其胞外结构域在信号传导中的关键作用，为靶向NRP1的肿瘤治疗提供结构基础。
2. **"Recombinant Neuropilin-1 protein inhibits VEGF-mediated angiogenesis in vitro and in vivo"**
- **作者**: Soker S, et al.
- **摘要**: 通过表达纯化重组NRP1蛋白，证明其可通过竞争性结合VEGF165阻断血管内皮细胞迁移和管状结构形成，提示其作为抗血管生成药物的潜力。
3. **"Expression and functional characterization of the soluble extracellular domain of Neuropilin-1"**
- **作者**: Gu C, et al.
- **摘要**: 成功在大肠杆菌中表达可溶性NRP1重组蛋白(sNRP1)，证实其抑制肿瘤细胞迁移和侵袭的能力，并阐明了其与肝素结合域的相互作用机制。
4. **"Targeted delivery of recombinant Neuropilin-1 protein enhances antitumor efficacy of chemotherapeutics"**
- **作者**: Parker MW, et al.
- **摘要**: 利用重组NRP1蛋白构建靶向纳米颗粒，显著提高化疗药物在NRP1高表达肿瘤中的富集，并减少对正常组织的毒性。
**建议**：通过PubMed或Google Scholar搜索关键词"recombinant Neuropilin-1"或"NRP1 protein purification"获取最新文献。部分研究可能涉及癌症、神经发育或免疫调节方向。
Neuropilin-1 (NRP1) is a single-pass transmembrane glycoprotein initially identified for its role in neuronal guidance and vascular development. It functions as a co-receptor for multiple signaling pathways, notably interacting with class 3 semaphorins (Sema3s) via its extracellular a1/a2 domains and vascular endothelial growth factor (VEGF) isoforms through its b1/b2 domains. NRP1 also contains a cytoplasmic domain that mediates intracellular signaling by binding to scaffolding proteins. Beyond its physiological roles in angiogenesis and axon guidance, NRP1 has gained attention in pathological contexts, including cancer progression, immune regulation, and viral entry (e.g., SARS-CoV-2 spike protein interaction).
Recombinant NRP1 proteins are engineered to mimic specific functional domains of the native protein, typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. These proteins often include the extracellular domains (a1/a2-b1/b2) responsible for ligand binding, enabling researchers to study receptor-ligand interactions in vitro. Applications include blocking VEGF- or Sema3-mediated signaling in cancer models, dissecting immune checkpoint mechanisms (e.g., NRP1’s role in regulatory T cell function), and developing therapeutic decoys to inhibit pathological angiogenesis or viral infection. Additionally, recombinant NRP1 serves as a critical tool in structural studies (e.g., crystallography) to map binding interfaces for drug design. Its versatility in both basic research and translational studies underscores its importance in understanding cell communication mechanisms and developing targeted therapies.
×
